Navigation Links
Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
Date:3/28/2011

Cellular and Molecular Biology 27Poster Section:

2Poster Board:

5The above abstracts are currently available online for viewing through the AACR 2011 Meeting website at: http://www.aacr.org/home/scientists/meetings--workshops/aacr-102nd-annual-meeting-2011/abstracts.aspx

KRX-0401 (perifosine) is in-licensed by Keryx from AEterna Zentaris Inc. in the United States, Canada and Mexico.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA.
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
3. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
6. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
7. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
8. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
9. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
10. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014  InfinityQS International, Inc., the ... today announces key client speakers for Infusion Chicago, ... . The event will be held Oct. 9-10, ... Presentations include projects from Coloplast, The Kellogg Company, ... Snak King. The two-day event will also include ...
(Date:10/2/2014)... , Oct. 2, 2014  Perrigo Company plc (NYSE: ... the laws of Ireland (the " ... exchange (the "Exchange Offer") up to $500,000,000 of its new ... "), $600,000,000 of its new 2.30% Senior Notes due 2018 ... 4.00% Senior Notes due 2023 (the " 2023 Exchange Notes ...
(Date:10/2/2014)... , Oct. 2, 2014   Softworld, Inc. ... a new practice solely focused on the specific needs ... While Softworld has already been highly successful in ... their additional capabilities to support the quality, regulatory, and ... is now a combination of the current Biometric team ...
Breaking Medicine Technology:InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 2InfinityQS Infusion Chicago to Spotlight Manufacturers' Key Successes in Achieving Enterprise Quality 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2
(Date:10/2/2014)... News) -- Scientists have pinpointed a molecule that may ... The researchers say this finding could offer a ... these attacks. Most asthma attacks (80 percent to ... airways, according to the British researchers. Most of these ... common cold. The researchers found that a specific ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... -- literally -- may face an increased risk of dying in ... of over 3,000 older Americans, researchers found those who were unable ... than three times as likely to die in the next five ... fact, anosmia -- the inability to distinguish odors -- was a ...
(Date:10/1/2014)... beta-amyloid is strongly associated with Alzheimer,s disease; however, researchers ... is the causal agent of the onset and development ... is that beta-amyloid is not harmful when found in ... it self-assembles to form the so-called amyloid fibrils , ... alone, but with multiple ones because each aggregate of ...
(Date:10/1/2014)... PA, October 1, 2014 Patients with increased ... have a greatly increased risk of depression. For ... for chronic hepatitis C virus infection causes depression ... fatty acids, more commonly known as fish oil, ... lowering the risk of heart disease and reducing ...
(Date:10/1/2014)... 01, 2014 Insuranceragents.info has released ... good life insurance plan for vulnerable family members. , ... family members. Providers in the family should always carry ... financial hardships for the rest of the family. ... Families can benefit more from temporary coverage or from ...
Breaking Medicine News(10 mins):Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
... colonised by E. coli bacteria early in life have ... a study of infants carried out at the Sahlgrenska Academy at ... outnumber the cells in our bodies by a factor of ten ... maturation of the immune system. The normal bacterial flora in the ...
... 2012) Autism Speaks is pleased to announce the launch ... in Toddlers, or M-CHAT. The M-CHAT is a scientifically validated ... age to assess their risk for autism spectrum disorder (ASD). ... Fein, Ph.D. and clinical psychologist Marianne Barton, Ph.D. The American ...
... Scientists who found a way to make white fat behave ... new obesity treatments. Brown fat burns energy (preventing obesity), ... cells are associated with fat accumulation around organs in the ... an increased risk for diabetes and heart disease, the researchers ...
... participation in a brief training program designed to ... in how patients perceived their interactions with the ... empathy with patients usually drops during medical school ... of Massachusetts General Hospital (MGH) researchers will appear ...
... against serious pneumococcal disease does not offer full protection, ... of Gothenburg, Sweden, finding that the number of cases ... Each year an estimated 1 million children worldwide die ... those in poor countries, but pneumococcal bacteria cause disease ...
... 6, 2012) - Eye color may be an indicator of ... A study, led by the University of Colorado School of ... have vitiligo. It then follows, according to scientists, that people ... Vitiligo is an autoimmune skin disease in which pigment loss ...
Cached Medicine News:Health News:Gut flora affects maturation of B cells in infants 2Health News:Automated autism screening tool available on Autism Speaks website 2Health News:Brief training program improves resident physicians' empathy with patients 2Health News:Brief training program improves resident physicians' empathy with patients 3Health News:Pneumococcal disease: More cases but fewer deaths 2Health News:Eye color may indicate risk for serious skin conditions 2
... are ideal for PCR and ... any work where aerosol contamination ... for pipetting DNA/RNA solutions, infectious ... For applications requiring absolute sterility, ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
... a safe alternative to using positive displacement ... such as PCR(a), pipetting radioactive materials and ... excellent for tissue culture, gel loading, serological ... aerosol contaminants and liquids from reaching the ...
... Finntip Filters are ideal ... amplification methods, or for ... contamination might occur. They ... DNA/RNA solutions, infectious materials, ...
Medicine Products: